Correction to the Reported Analytic Sample Size in the Results
-
November 1, 2026
Clinical Scorecard: Correction to the Reported Analytic Sample Size in the Results
At a Glance
| Category | Detail |
|---|---|
| Condition | Statin eligibility according to atherosclerotic cardiovascular disease risk in the US |
| Key Mechanisms | Not described in the correction notice. |
| Target Population | The analytic sample in the original investigation; the correction notice does not provide further population details. |
| Care Setting | US population-level analysis of statin eligibility; the correction notice does not specify a clinical care setting. |
Key Highlights
- The original investigation was published online on August 20, 2025, and subsequently in the October 2025 issue.
- The analytic sample size reported in the results was corrected from 133.6 million to 113.6 million.
- The article has been corrected online.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
The correction notice identifies an analytic sample of 113.6 million but provides no additional patient characteristics.
The notice concerns a correction to the reported sample size and provides no prescribing or treatment details.
Clinical Best Practices
Related Resources & Content
Based on findings from:
Error in Results
Jama Cardiology, 2026.
https://jamanetwork.com/journals/jamacardiology/fullarticle/2853793
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.